Advertisement

A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)

Published:April 23, 2022DOI:https://doi.org/10.1016/j.clgc.2022.04.008

      Highlights

      • Systemic adjuvant chemotherapy for muscle-invasive bladder carcinoma is controversial.
      • Systemic adjuvant chemotherapy for muscle-invasive upper tract urothelial carcinoma improves disease-free survival, however with considerable toxicity.
      • Systemic immune checkpoint inhibitors (ICI) were evaluated in the adjuvant treatment setting with lower risk of toxicity, however with conflicting clinical benefit.
      • After meta-analysis of the ICI available data in the adjuvant setting there was no clinical benefit associate.

      Abstract

      Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of high-risk MIUC patients. However, conflicting data from another randomized controlled trial (RCT) with atezolizumab makes the benefit of this treatment uncertain. We performed a systematic review and study-level meta-analysis to evaluate the benefit in terms of disease-free survival (DFS) with ICI adjuvant treatment for patients with high-risk MIUC. Considering the Preferred Reporting Items for Systematic Review statement, a systematic search was performed in PUBMED/MEDLINE, Scopus and EMBASE up to October 30, 2021. The statistical analysis was performed by RevMan 5.4 software in intention-to-treat (ITT) population and in predetermined subgroups. Two RCTRCT, with a total of 1518 patients, met the inclusion criteria. Systemic immunotherapy was atezolizumab for 406 patients and nivolumab for 353 patients. In the ITT population there was a nonsignificant benefit with the systemic adjuvant immunotherapy (HR:0.79, 95% CI 0.62-1.00; z = 2.00) but with high heterogeneity (I2 = 65%). Regarding the subgroups, there was no benefit in PD-L1 negative (HR:0.81, 95% CI 0.70-1.00; z = 1.96, I2 = 0%) and in non-neoadjuvant chemotherapy (HR:0.95, 95% CI 0.78-1.15; z = 0.56, I2 = 0%). Adjuvant treatment with ICI to patients with high-risk MIUC reveals a nonsignificant impact in DFS. The lack of clinical benefit was demonstrated in all subgroups. These data reinforce the need for a careful selection of patients before offering this approach in daily practice.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Reference

        • Stein JP
        • Lieskovsky G
        • Cote R
        • et al.
        Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
        J Clin Oncol. 2001; 19: 666-675
        • Sternberg CN
        • Donat SM
        • Bellmunt J
        • et al.
        Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
        Urology. 2007; 69 (Suppl): 62-79
        • Huo J
        • Ray-Zack MD
        • Shan Y
        • et al.
        Discerning patterns and quality of neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer.
        Eur Urol Oncol. 2019; 2: 497-504
        • Au D
        • Lee EK
        • Popoola TO
        • Parker WP
        • Onge JMS
        • Ellis SD.
        Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.
        Int Braz J Urol. 2021; 47: 803-818
        • Nyame YA
        • Holt SK
        • Diamontopoulos LN
        • et al.
        Social and clinical correlates of neoadjuvant chemotherapy in medicare beneficiaries with muscle invasive bladder cancer from 2004-2015.
        Urology. 2021; 149: 154-160
        • Paz-Ares LG
        • Solsona E
        • Esteban E
        • et al.
        Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.
        Journal of Clinical Oncology. 2010; 28 (LBA4518-LBA)
        • Cognetti F
        • Ruggeri EM
        • Felici A
        • et al.
        Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
        Ann Oncol. 2012; 23: 695-700
        • Sternberg CN
        • Skoneczna I
        • Kerst JM
        • et al.
        Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
        Lancet Oncol. 2015; 16: 76-86
        • Powles T
        • Park SH
        • Voog E
        • et al.
        Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2020; 383: 1218-1230
        • Fradet Y
        • Bellmunt J
        • Vaughn DJ
        • et al.
        Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
        Ann Oncol. 2019; 30: 970-976
        • Necchi A
        • Raggi D
        • Gallina A
        • et al.
        Updated results of pure-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies.
        Eur Urol. 2020; 77: 439-446
        • Hoimes CJ
        • Adra N
        • Fleming MT
        • et al.
        Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.
        J Clin Oncol. 2020; 38 (-): 5047
        • Gupta S
        • Sonpavde G
        • Weight CJ
        • et al.
        Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.
        J Clin Oncol. 2020; 38 (-): 439
        • van Dijk N
        • Gil-Jimenez A
        • Silina K
        • et al.
        Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
        Nat Med. 2020; 26: 1839-1844
        • Bellmunt J
        • Hussain M
        • Gschwend JE
        • et al.
        Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2021; 22: 525-537
        • Bajorin DF
        • Witjes JA
        • Gschwend JE
        • et al.
        Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.
        New England J Med. 2021; 384: 2102-2114
        • Page MJ
        • McKenzie JE
        • Bossuyt PM
        • et al.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        BMJ. 2021; 372: n71
        • Turner L
        • Boutron I
        • Hróbjartsson A
        • Altman DG
        • Moher D.
        The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration.
        Systemat Rev. 2013; 2: 79
        • Hróbjartsson A
        • Kaptchuk TJ
        • Miller FG.
        Placebo effect studies are susceptible to response bias and to other types of biases.
        J Clin Epidemiol. 2011; 64: 1223-1229
        • Hendry S
        • Byrne DJ
        • Wright GM
        • et al.
        Comparison of four PD-L1 immunohistochemical assays in lung cancer.
        J Thoracic Oncol. 2018; 13: 367-376
        • Zajac M
        • Scott M
        • Ratcliffe M
        • et al.
        Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
        Diagnostic Pathol. 2019; 14: 99
        • Galsky MD
        • Arija JÁ A
        • Bamias A
        • et al.
        Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
        Lancet. 2020; 395: 1547-1557
        • Powles T
        • van der Heijden MS
        • Castellano D
        • et al.
        Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
        Lancet Oncol. 2020; 21: 1574-1588
        • Powles T
        • Csőszi T
        • Özgüroğlu M
        • et al.
        Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 931-945
        • Laukhtina E
        • Sari Motlagh R
        • Mori K
        • et al.
        Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.
        Crit Rev Oncol Hematol. 2021; 169103570
        • Kamoun A
        • de Reyniès A
        • Allory Y
        • et al.
        A consensus molecular classification of muscle-invasive bladder cancer.
        Eur Urol. 2020; 77: 420-433
        • Sharma P
        • Retz M
        • Siefker-Radtke A
        • et al.
        Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2017; 18: 312-322
        • Berndl F
        • Hassler MR.
        Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
        Curr Opin Urol. 2022; 32: 48-53
        • Robinson BD
        • Vlachostergios PJ
        • Bhinder B
        • et al.
        Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
        Nat Commun. 2019; 10: 2977
        • Yang K
        • Yu W
        • Liu H
        • et al.
        Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder.
        Oncologist. 2021; 26: e1395-ee405
        • Esagian SM
        • Khaki AR
        • Diamantopoulos LN
        • et al.
        Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
        BJU Int. 2021; 128: 196-205
        • Thouvenin J
        • Martínez Chanzá N
        • Alhalabi O
        • et al.
        Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and future directions.
        Cancers (Basel). 2021; 13: 4341
        • Bersanelli M
        • Buti S
        • Giannatempo P
        • et al.
        Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
        Crit Rev Oncol Hematol. 2021; 159103241
        • Ariafar A
        • Ghaedi M
        • Rezaeifard S
        • et al.
        Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: a role for PD-L2.
        Mol Immunol. 2020; 124: 35-41
        • Latchman Y
        • Wood CR
        • Chernova T
        • et al.
        PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
        Nat Immunol. 2001; 2: 261-268
        • George S
        • Papanicolau-Sengos A
        • Lenzo FL
        • et al.
        PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.
        Oncoimmunology. 2018; 7e1460298
        • Chen Y
        • Pei Y
        • Luo J
        • Huang Z
        • Yu J
        • Meng X.
        Looking for the optimal PD-1/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice.
        Front Immunol. 2020; 11: 1088
        • Duan J
        • Cui L
        • Zhao X
        • Bai H
        • et al.
        Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis.
        JAMA Oncol. 2020; 6: 375-384
        • Umezu D
        • Okada N
        • Sakoda Y
        • et al.
        Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
        Cancer Immunol Immunother. 2019; 68: 201-211
        • Powles T
        • Assaf ZJ
        • Davarpanah N
        • et al.
        ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
        Nature. 2021; 595: 432-437
      1. A study of atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who Are ctDNA positive following cystectomy (IMvigor011). [December 20, 2021 ]. Available from: https://clinicaltrials.gov/ct2/show/NCT04660344.

      2. Testing MK-3475 (Pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer (AMBASSADOR) [December 15, 2021 ]. Available from: https://clinicaltrials.gov/ct2/show/NCT03244384.